GMED logo
GMED
Globus Medical

Integration With NuVasive And Rollout Of Excelsius And XR Headset Will Fuel Future Market Expansion

AN
AnalystConsensusTarget
AnalystConsensusTarget
Not Invested
Consensus Narrative from 11 Analysts
Published
25 Aug 24
Updated
07 Aug 25
AnalystConsensusTarget's Fair Value
US$83.00
34.9% undervalued intrinsic discount
07 Aug
US$54.07
Loading
1Y
-26.9%
7D
2.7%

Author's Valuation

US$83.0

34.9% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Narrative
Updates9

Shared on07 May 25
Fair value Decreased 16%

Read more

Shared on30 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on17 Apr 25
Fair value Decreased 0.63%

AnalystConsensusTarget has increased revenue growth from 6.7% to 7.6%.

Read more

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on02 Apr 25
Fair value Increased 1.26%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on19 Mar 25
Fair value Decreased 0.63%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on10 Mar 25
Fair value Increased 16%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more